GLP-1 agonists like Ozempic lower cancer risks in study
Summary: A study in JAMA suggests GLP-1 agonists, including Ozempic, reduce the risk of certain obesity-related cancers. Patients with Type 2 diabetes on these drugs had significantly lower risks of 10 out of 13 cancers studied. GLP-1 agonists like Ozempic may break the link between obesity and cancer. This could lead to more doctors prescribing these drugs over insulin for diabetes treatment.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings